Aptevo secures $60M equity line with Yorkville, extends funding runway into 2029

Aptevo Therapeutics Inc.

Enters $60M Standby Equity Purchase Agreement with Yorkville; minimal fees, no warrants.
Company has right to sell shares at 96% of lowest 3-day VWAP; capped at ~199,466 shares without approval.
Fully leveraged facility plus cash on hand expected to extend funding into 2029.
Proceeds to support pipeline including mipletamig (CD123xCD3) in Phase 1b/2 frontline AML trial.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Aptevo Therapeutics Inc. entered into Standby Equity Purchase Agreement with YA II PN, LTD. valued at up to $60.0 million (effective 2026-01-08).

Action: entry
Agreement: equity purchase
Counterparty: YA II PN, LTD.
Value: up to $60.0 million
Effective: 2026-01-08

Exact text from the filing

On January 8, 2026, Aptevo Therapeutics Inc. (the "Company") entered into a Standby Equity Purchase Agreement (the "Purchase Agreement") with YA II PN, LTD., a Cayman Islands exempt limited company ("Yorkville"). Pursuant to the Purchase Agreement, the Company has the right, but not the obligation, to issue and sell to Yorkville from time to time (each such occurrence, an "Advance") up to $60.0 million (the "Commitment Amount") of the Company's common stock

View on SEC.gov

329 material agreements filed in the last 30 days. Browse all material agreements →

Aptevo Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-008318

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.